A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant loss of -11.43% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -24.94%. Over the past 30 days, the price of MREO has leaped by -5.78%. And in the last five days, it has surged by 2.31%.
Mereo Biopharma Group Plc ADR’s stock has seen a smooth market performance.
52-week price history of MREO Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Mereo Biopharma Group Plc ADR’s current trading price is -38.25% away from its 52-week high, while its distance from the 52-week low is 22.77%. The stock’s price range for this period has been between $2.53 and $5.02. The Healthcare sector company’s shares saw a trading volume of about 1.51 million for the day, which was higher than the average daily volume of 0.99 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Mereo Biopharma Group Plc ADR (MREO) has experienced a quarterly decline of -31.57% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 479.66M and boasts a workforce of 33 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.93, with a change in price of -1.57. Similarly, Mereo Biopharma Group Plc ADR recorded 894,603 in trading volume during the last 100 days, posting a change of -33.62%.
MREO’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for MREO stands at 0.09. Similarly, the long-term debt-to-equity ratio is also 0.01.
MREO Stock Stochastic Average
As of today, the raw stochastic average of Mereo Biopharma Group Plc ADR over the past 50 days is 18.81%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 27.78%. Additionally, the Stochastic %K and %D values for the company were 18.83% and 13.27%, respectively, over the past 20 days.
